Tuesday, February 28, 2023
Jupiter Neurosciences, Inc., a clinical-stage pharmaceutical company advancing a pipeline focused on the treatment of central nervous system (CNS) disorders and rare diseases, today announced topline proof-of-concept preclinical data with its proprietary resveratrol drug product, JOTROL™, for Parkinson's Disease (PD). In collaboration with scientists Shaun Brothers, PhD, MBA and Candace Carriere, PhD at the University of Miami School of Medicine, the Company recently completed preclinical activities in a validated mouse model of PD. This model of PD mimics many aspects of the disease utilizing a unilateral injection of a neurotoxin precursor that elicits nigral cell loss, striatal dopamine loss and behavior deficits similar to physiological characteristics of human Parkinson's disease.
Statistically significant positive outcomes, particularly in the endpoint of enhanced grip strength, has now been established in two preclinical indications, PD and MPSI. Grip strength is a key physical manifestation of the disease, a motor score used to measure the severity and progression of PD. Improvement of grip strength is a disease modifying breakthrough for patients suffering with Parkinson's. Additional findings include JOTROL™ significantly improving an outcome used to evaluate motor coordination, rotarod performance; significantly improving behavioral characteristics induced in the animal model; as well as being generally safe and well tolerated.
"These exciting data support our nomination of JNS115 as our next development project and our entrance into the PD population with JOTROL™. JNS115 is a clear strategic priority for the Company," commented Alison Silva, President & CBO. "This research demonstrates the neuroprotectant abilities of JOTROL™ as a potential treatment to prevent onset and progression of PD symptoms. We look forward to advancing this program with a partner, as well as continuing to advance our internal rare disease and ongoing MCI/ early Alzheimer's Disease programs."